Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib versus placebo with supportive care in non-small cell lung cancer after failure of erlotinib or gefitinib
2007-005983-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Afatinib + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2008; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-005983-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005983-28.